[Benefits of oxygen on exercise performance in patients with chronic lung diseases].

Pneumonol Alergol Pol

Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii WUM, ul. Banacha 1a; 02–097 Warszawa, Poland.

Published: August 2014


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Chronic respiratory diseases limit exercise capacity, due to breathlessness and hypoxemia. A decrease in daily activity results in impairment of quality of life and higher mortality. Oxygen therapy improves exercise capacity. The main mechanism of this improvement in COPD patients is a reduction in dynamic hyperinflation. The benefits of oxygen therapy is present not only in patients with severe hypoxemia at rest (PaO2 < 60 mm Hg) requiring long-term oxygen therapy, but also in mild hypoxemic patients who develop desaturation during exercise. An improvement in exercise tolerance is proportional to the administered oxygen flow. Provision of oxygen flow from ambulatory source may be continuous or intermittent only during inspiration. Both methods seem to be comparable in terms of improving exercise tolerance and reducing hypoxemia. Ambulatory oxygen should be prescribed to all patients on long-term oxygen therapy who report outdoor activity. Moreover, normoxemic patients with severe exertional desaturation and low exercise tolerance should also be prescribed ambulatory oxygen. The flow of oxygen should be titrated to prevent desaturation during activities. The long-term effects of ambulatory oxygen such as improvement of quality of life and increasing daily activity have not been confirmed and require further investigation.

Download full-text PDF

Source

Publication Analysis

Top Keywords

oxygen therapy
16
exercise tolerance
12
oxygen flow
12
ambulatory oxygen
12
oxygen
10
exercise capacity
8
daily activity
8
quality life
8
patients severe
8
long-term oxygen
8

Similar Publications

Joint disorders and ozone therapy: some comments.

Inflammopharmacology

September 2025

Department of Engineering for Innovation Medicine, University of Verona, Strada Le Grazie 8, 37134, Verona, Italy.

View Article and Find Full Text PDF

Decades of antibiotic misuse have spurred an antimicrobial resistance crisis, creating an urgent demand for alternative treatment options. Although phototherapy has therapeutic potential, the efficacy of the most advanced photosensitizers (PS) is essentially limited by aggregation-induced quenching, which significantly reduces their therapeutic effect. To address these challenges, we developed a cationic metallocovalent organic framework (CRuP-COF) via a solvent-mediated dual-reaction synthesis strategy.

View Article and Find Full Text PDF

Neuromuscular diseases are often accompanied by various types of sleep-related breathing disorders, which can exacerbate the underlying condition and are associated with a poor prognosis. Early identification is essential, and interventions such as non-invasive ventilation, oxygen therapy, and respiratory rehabilitation should be initiated promptly to mitigate disease progression and improve outcomes. Nevertheless, the rates of missed and misdiagnosed cases remain common in clinical practice.

View Article and Find Full Text PDF

Efficacy of JAK inhibitor combined with protein A immunoadsorption in MDA5+ dermatomyositis with RPILD: A real-world study.

Med

September 2025

Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200000, China; Academy for Clinical Innovation and Translation of Shanghai, Shanghai 200000, China. Electronic address:

Background: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5+ DM) with rapidly progressive interstitial lung disease (RPILD) is a fatal disease. Although Janus kinase inhibitors (JAKi) hold their promise in treating MDA5+ DM, regimen for RPILD is still urgently needed to improve the adverse prognosis.

Methods: Based on a large inception cohort of MDA5+ DM, patients with RPILD (oxygen index [OI] < 300 within the first 3 months of disease duration) were included.

View Article and Find Full Text PDF

Harnessing the significant buildup of lactic acid (LA) within the tumor microenvironment (TME) for metabolic manipulation presents a promising avenue for cancer treatment. Nevertheless, single-agent therapies often fail to address the complex and varying needs of TME heterogeneity, posing a substantial scientific hurdle in oncology. In this context, we employ asymmetric mesoporous silica nanoparticles (AMS NPs) as delivery vehicles, simultaneously loading them with zinc‑cobalt‑manganese ferrite nanoparticles (ZCMF NPs), lactate oxidase (LOX), and doxorubicin (DOX).

View Article and Find Full Text PDF